Morales-Sánchez MA, Peralta-Pedrero ML, Cruz-Peñaloza LC

Language: Spanish
References: 19
Page: 91-95
PDF size: 192.31 Kb.

ABSTRACT

Introduction: there are many risk factors that have been associated with the development of vitiligo, however, reported epidemiological data are scarce. The objective of the work carried out, reported in this article, was to determine the prevalence of risk factors that have been associated with the development of vitiligo. Material and methods: a cross-sectional survey-type study was carried out via email in adults with non-segmental vitiligo who attended the "Dr. Ladislao de la Pascua" Dermatological Center. Results: 26 questionnaires were received, of which 76.9% of the participants reported being exposed to at least one chemical product associated as a risk factor for vitiligo. 76.92% (n = 20) were related to anilines in nickel, 42.30% (n = 11) anilines in perfumes, 42.30% (n = 11) cobalt as porcelain, 30.76% (n = 8) chrome as faucets, 30.76% (n = 8) anilines in thinner, 3.84% (n = 1) organic solvents, 3.84% (n = 1) anilines in paints and 3.84% (n = 1) pesticides. 30.8% of patients had at least one sunburn throughout their lives and 84.6% of patients were exposed to the sun continuously during the last year. Conclusion: cohort studies are required to identify whether exposure to chemicals and sun exposure are risk factors for the development of vitiligo in our population.

REFERENCES

1. Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. 2020; 236: 571-592. doi: 10.1159/000506103.

2. Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC et al. Revised classification/nomenclature of vitiligo and related issues: The Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012; 25: E1-13. doi: 10.1111/j.1755-148X.2012.00997.x.

3. Sehgal VN, Srivastava G. Vitiligo: compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol. 2007; 73: 149-156. doi: 10.4103/0378-6323.32708.

4. Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res. 2003; 16: 208-214. doi: 10.1034/j.1600-0749.2003.00032.x.

5. Mohammed GF, Gomaa AH, Al-Dhubaibi MS. Highlights in pathogenesis of vitiligo. World J Clin Cases. 2015; 3: 221-230. doi: 10.12998/wjcc.v3.i3.221.

6. Frisoli ML, Essien K, Harris JE. Vitiligo: mechanisms of pathogenesis and treatment. Annu Rev Immunol. 2020; 38: 621-648. doi: 10.1146/annurev-immunol-100919-023531.

7. Chaweekulrat P, Silpa-Archa N, Apinuntham C, Chaiyabutr C, Wongpraparut C. Reliability, validity and feasibility of the Vitiligo Extent Score (VES) and Self-Assessment Vitiligo Extent Score (SA-VES) among vitiligo patients: a cross-cultural validation. Clin Cosmet Investig Dermatol. 2021; 14: 949-957. doi: 10.2147/CCID.S324073.

8. Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE; Vitiligo Working Group. Current and emerging treatments for vitiligo. J Am Acad Dermatol. 2017; 77: 17-29. doi: 10.1016/j.jaad.2016.11.010.

9. Quan C, Ren YQ, Xiang LH, Sun LD, Xu AE, Gao XH et al. Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. Nat Genet. 2010; 42: 614-618. doi: 10.1038/ng.603.

10. Kotobuki Y, Tanemura A, Yang L, Itoi S, Wataya-Kaneda M, Murota H et al. Dysregulation of melanocyte function by Th17-related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris. Pigment Cell Melanoma Res. 2012; 25: 219-230. doi: 10.1111/j.1755-148X.2011.00945.x.

11. Ohguchi R, Kato H, Furuhashi T, Nakamura M, Nishida E, Watanabe S et al. Risk factors and treatment responses in patients with vitiligo in Japan-A retrospective large-scale study. Kaohsiung J Med Sci. 2015; 31: 260-264. doi: 10.1016/j.kjms.2015.02.003.

12. Ezzedine K, Diallo A, Léauté-Labreze C, Mossalayi D, Gauthier Y, Bouchtnei S et al. Multivariate analysis of factors associated with early-onset segmental and nonsegmental vitiligo: a prospective observational study of 213 patients. Br J Dermatol. 2011; 165: 44-49. doi: 10.1111/j.1365-2133.2011.10311.x.

13. Dunlap R, Wu S, Wilmer E, Cho E, Li WQ, Lajevardi N et al. Pigmentation traits, sun exposure, and risk of incident vitiligo in women. J Invest Dermatol. 2017; 137: 1234-1239. doi: 10.1016/j.jid.2017.02.004.

14. Jeon IK, Park CJ, Lee MH, Lee DY, Kang HY, Hann SK et al. A multicenter collaborative study by the Korean Society of Vitiligo about patients' occupations and the provoking factors of vitiligo. Ann Dermatol. 2014; 26: 349-356. doi: 10.5021/ad.2014.26.3.349.

15. Vrijman C, Hosseinpour D, Bakker JG, Wolkerstorfer A, Bos JD, van der Veen JP et al. Provoking factors, including chemicals, in Dutch patients with vitiligo. Br J Dermatol. 2013; 168: 1003-1011. doi: 10.1111/bjd.12162.

16. van Geel N, Speeckaert R, De Wolf J, Bracke S, Chevolet I, Brochez L et al. Clinical significance of Koebner phenomenon in vitiligo. Br J Dermatol. 2012; 167: 1017-1024. doi: 10.1111/j.1365-2133.2012.11158.x.

17. Mahajan VK, Verma YR, Mehta KS, Chauhan PS, Sharma R, Sharma A et al. Adults with a more extensive body involvement, moderate to extremely severe vitiligo and a prolonged clinical course have an early onset in childhood in addition to other prognostic factors as compared to individuals with later-onset vitiligo. Australas J Dermatol. 2021; 62: e24-e28. doi: 10.1111/ajd.13417.

18. 18 . Benzekri L, Gauthier Y, Hamada S, Hassam B. Clinical features and histological findings are potential indicators of activity in lesions of common vitiligo. Br J Dermatol. 2013; 168: 265-271. doi: 10.1111/bjd.12034.

19. Kanwar AJ, Mahajan R, Parsad D. Type 2A Koebner phenomenon in vitiligo is distinct from other subtypes: observations from an Indian cohort. Br J Dermatol. 2014; 170: 586-590. doi: 10.1111/bjd.12651.